← Back to Home

Pancreatic Cancer Vaccine Triggers Immune Response in Nearly 99% of Participants, but Phase 2 Trial Does Not Demonstrate Delayed Recurrence

Camupepimut enabled T cells in most evaluable patients to recognize mutant KRAS, but failed to meet the primary endpoint of disease-free survival. The gap between this immune response and tumor control is becoming the focus of the next round of research.

By SURL BioNews

Preventing pancreatic cancer from returning after surgical removal remains an unresolved treatment challenge. An experimental vaccine, camupepimut, has delivered a striking but complex answer: nearly all evaluable vaccine recipients developed an immune response against cancer markers, but a randomized trial did not demonstrate that this was sufficient to significantly extend the time patients remained free of recurrence or death. “Nearly 99% developed an immune response” therefore cannot be interpreted as treatment being effective in nearly 99% of patients.

The phase 2 AMPLIFY-7P study, published in *Nature Medicine* on October 23, enrolled 144 patients with KRAS-mutated pancreatic ductal adenocarcinoma at 24 sites in the United States. They had undergone surgery and chemotherapy and had no imaging evidence of recurrence at enrollment; 96 received the vaccine, while 48 underwent standard observation. Median disease-free survival was 23.8 and 21.2 months, respectively, with a hazard ratio of 0.85 and a P value of 0.5329. The trial did not meet its prespecified primary endpoint.

Camupepimut, also known as ELI-002 7P, contains peptides corresponding to seven common KRAS mutations and an immune adjuvant. Its lipid design allows it to bind to albumin, helping vaccine components reach lymph nodes so immune cells can learn to recognize the mutant markers. Among 90 vaccine recipients with evaluable immune data, 89 showed an increase in mutant KRAS-specific T-cell responses, or 98.9%; the denominator for this figure was not all 144 trial participants.

An exploratory analysis showed that vaccine recipients with stronger immune responses also had longer disease-free survival. However, comparing patients according to the strength of their responses after vaccination cannot establish that the vaccine caused the survival difference. Developer Elicio also noted that a higher proportion of patients in the vaccine group had detectable circulating tumor DNA in their blood at enrollment: 20.8%, compared with 12.5% in the observation group. Such prognostic differences help explain the results, but post hoc statistical adjustments cannot replace the primary analysis, which did not meet its endpoint.

For safety, the proportions of patients with grade 3 or higher adverse events were 10.4% and 14.6% in the two groups, respectively. Elicio said no new safety signals were identified. The company plans to discuss a potential phase 3 trial with regulators, including how to stratify patients by prognostic factors, adjust treatment duration, and evaluate combination treatments; these remain plans for further development.

Background

Treatments targeting RAS can directly block signaling in cancer cells or attempt to teach the immune system to recognize mutations. Whether these two approaches can complement each other is the next question for the University of Miami’s Sylvester Comprehensive Cancer Center. The center has received a total of $1 million in research funding over five years to analyze stored tumor specimens from trial participants and identify factors in the tumor environment that limit vaccine-induced immune responses.

The team also plans to test camupepimut combined with the RAS inhibitor daraxonrasib in preclinical studies and compare the effects with and without the immunotherapy drug nivolumab. These experiments aim to clarify why T cells may still fail to control tumors even after learning to recognize their targets. Until evidence from human trials is available for combination strategies, these results provide a reason for continued research but are not yet sufficient to establish that the vaccine can reduce the risk of recurrence.

References

  1. healthandme
  2. Nature Medicine
  3. Elicio Therapeutics Inc. via GlobeNewswire
  4. University of Miami Miller School of Medicine